News

We provide the latest news
from the world of economics and finance

Back
22 January
Lobbying Update: $2,440,000 of GILEAD SCIENCES INC lobbying was just disclosed

$2,440,000 of GILEAD SCIENCES INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"International trade and protection of intellectual property; TRIPS Waiver; global supply chain issues, including the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.
Funding for and policies relating to Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Legislative and regulatory proposals to change international and domestic corporate tax law and policy."

You can find more data on corporate lobbying on Quiver Quantitative.

GILD Congressional Stock Trading

Members of Congress have traded $GILD stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:

  • REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 12/24.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

GILD Insider Trading Activity

GILD insiders have traded $GILD stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.

Here’s a breakdown of recent trading of $GILD stock by insiders over the last 6 months:

  • ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 4 sales selling 259,645 shares for an estimated $24,075,305.
  • MERDAD PARSEY (Chief Medical Officer) has made 0 purchases and 9 sales selling 213,047 shares for an estimated $19,398,445.
  • JOHANNA MERCIER (Chief Commercial Officer) has made 0 purchases and 5 sales selling 49,360 shares for an estimated $4,064,426.
  • JEFFREY BLUESTONE sold 6,788 shares for an estimated $620,355

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

GILD Hedge Fund Activity

We have seen 750 institutional investors add shares of GILD stock to their portfolio, and 810 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • FMR LLC added 14,680,161 shares (+79.4%) to their portfolio in Q3 2024, for an estimated $1,230,784,698
  • WELLINGTON MANAGEMENT GROUP LLP added 11,665,593 shares (+50.9%) to their portfolio in Q3 2024, for an estimated $978,043,317
  • PACER ADVISORS, INC. removed 7,108,073 shares (-90.1%) from their portfolio in Q3 2024, for an estimated $595,940,840
  • CITADEL ADVISORS LLC added 4,739,526 shares (+1702.5%) to their portfolio in Q3 2024, for an estimated $397,361,859
  • TWO SIGMA ADVISERS, LP removed 3,767,900 shares (-60.2%) from their portfolio in Q3 2024, for an estimated $315,900,736
  • TWO SIGMA INVESTMENTS, LP removed 2,634,933 shares (-79.0%) from their portfolio in Q3 2024, for an estimated $220,912,782
  • D. E. SHAW & CO., INC. removed 2,597,051 shares (-77.8%) from their portfolio in Q3 2024, for an estimated $217,736,755

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

This article was originally published on Quiver News, read the full story.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.